Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626

J. W. Goodwin, S. J. Green, S. Giarritta, J. K. Giguere, K. Hoelzer, J. Bearden, R. B. Livingston, J. Gralow, P. A. Ganz, S. Martino, K. S. Albain

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626'. Together they form a unique fingerprint.

Medicine & Life Sciences